As of Jun 30, 2026, Halozyme Therapeutics, Inc. had total assets of $2.6 billion and total liabilities of $2.4 billion. Total assets were up 25.5% from a year earlier. Stockholders' equity was $143.5 million. It held $163.1 million in cash and investments against $2.2 billion of total debt, net debt of $2.0 billion. The current ratio, current assets divided by current liabilities, was 2.71.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash |
163
+163.7%
|
310
+75.7%
|
134
+15.5%
|
420
+171.9%
|
62
-67.1%
|
176
+7.1%
|
116
-2.1%
|
154
-43.7%
|
| Cash and investments |
163
+163.7%
|
310
+75.7%
|
134
+15.5%
|
420
+171.9%
|
62
-67.1%
|
176
+7.1%
|
116
-2.1%
|
154
-43.7%
|
| Receivables |
453
+43.9%
|
458
+50.6%
|
426
+47.9%
|
344
+25.8%
|
315
+49.7%
|
304
+64.1%
|
288
|
273
+27.6%
|
| Inventory |
137
-24.4%
|
155
-5.7%
|
176
+24.4%
|
186
+41.4%
|
182
+13.9%
|
165
-2.2%
|
142
+11.2%
|
131
+1.9%
|
| Total current assets |
933
-16.9%
|
1,003
-20.5%
|
825
-24.0%
|
1,329
+17.9%
|
1,123
+13.7%
|
1,262
+44.5%
|
1,085
+45.4%
|
1,127
+28.2%
|
| Property and equipment, net |
50
+25.7%
|
47
+16.7%
|
44
+8.8%
|
41
+1.5%
|
40
-1.5%
|
40
-4.0%
|
41
+7.2%
|
40
+6.7%
|
| Goodwill |
582
+39.6%
|
582
+39.7%
|
580
+39.2%
|
417
+0.0%
|
417
+0.0%
|
417
+0.0%
|
417
+0.0%
|
417
+0.0%
|
| Total assets |
2,577
+25.5%
|
2,673
+21.7%
|
2,525
+22.4%
|
2,221
+4.9%
|
2,054
+4.3%
|
2,197
+19.3%
|
2,063
+19.1%
|
2,118
+11.9%
|
| Liabilities and equity | ||||||||
| Accounts payable |
24
+26.3%
|
14
-29.8%
|
21
+103.9%
|
15
+23.9%
|
19
+21.1%
|
20
+50.6%
|
10
-13.3%
|
12
-35.8%
|
| Total current liabilities |
344
+156.5%
|
363
+141.5%
|
177
+27.3%
|
837
+669.4%
|
134
+0.7%
|
150
+14.2%
|
139
+23.7%
|
109
-5.5%
|
| Total liabilities |
2,434
+41.4%
|
2,453
+43.1%
|
2,477
+45.7%
|
1,717
+3.1%
|
1,721
+2.4%
|
1,714
+3.0%
|
1,700
+3.0%
|
1,665
+1.3%
|
| Stockholders' equity |
144
-56.9%
|
220
-54.5%
|
49
-86.6%
|
504
+11.3%
|
333
+15.0%
|
482
+171.2%
|
364
+334.1%
|
453
+81.7%
|
| Debt | ||||||||
| Debt due within a year |
209
|
209
|
—
|
711
|
—
|
—
|
—
|
—
|
| Long-term debt |
1,938
+28.4%
|
1,936
+28.4%
|
2,143
+42.3%
|
800
-46.8%
|
1,509
+0.4%
|
1,507
+0.4%
|
1,506
+0.4%
|
1,504
+0.4%
|
| Lease liabilities |
32
+10.0%
|
32
+10.3%
|
35
+12.6%
|
28
-8.6%
|
29
-5.5%
|
29
-7.5%
|
31
-4.6%
|
31
-5.0%
|
| Total debt |
2,179
+41.6%
|
2,177
+41.7%
|
2,177
+41.7%
|
1,539
+0.3%
|
1,538
+0.3%
|
1,537
+0.3%
|
1,537
+0.3%
|
1,535
+0.3%
|
| Net cash |
-2,015
-36.5%
|
-1,867
-37.3%
|
-2,043
-43.8%
|
-1,119
+18.9%
|
-1,476
-9.7%
|
-1,361
+0.5%
|
-1,421
-0.5%
|
-1,381
-9.9%
|
| Ratios | ||||||||
| Current ratio |
2.71x
|
2.76x
|
4.66x
|
1.59x
|
8.36x
|
8.39x
|
7.80x
|
10.36x
|
| Debt to equity |
15.18x
|
9.91x
|
44.60x
|
3.05x
|
4.62x
|
3.19x
|
4.22x
|
3.39x
|
| Debt to EBITDA |
3.56x
|
4.15x
|
4.53x
|
2.06x
|
2.22x
|
2.53x
|
2.74x
|
3.15x
|
| Return on equity |
288.13%
|
158.83%
|
649.18%
|
118.17%
|
167.48%
|
100.64%
|
122.06%
|
86.69%
|
| Return on assets |
16.05%
|
13.05%
|
12.55%
|
26.81%
|
27.13%
|
22.10%
|
21.52%
|
18.53%
|
| Book value per share |
1.26
|
1.85
|
0.41
|
4.29
|
2.83
|
3.92
|
2.95
|
3.56
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HALO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1159036
- Former names
- HALOZYME THERAPEUTICS INC (until Jul 3, 2019); GLOBAL YACHT SERVICES INC (until Mar 12, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.